Marjolin's Ulcer in Patients With Anogenital Lichen Planus: A Systematic Review
Miranda K Branyiczky1, Megan S Lowe2, Mohannad Abu-Hilal1,3
1Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
None:
Anogenital lichen planus (ALP) is a chronic inflammatory condition associated with significant morbidity and a potential risk of cutaneous squamous cell carcinoma (cSCC), specifically Marjolin ulcer (MU), a rare, but aggressive, life-threatening complication. This systematic review aimed to describe the clinical characteristics of patients developing MU within ALP and its treatment outcomes. MEDLINE and Embase (inception-November 2024) were searched, identifying studies reporting MU or squamous dysplasia arising within ALP lesions. Thirty-two studies (n = 176 cases) were analyzed, including cohort studies, case series, and reports, and a descriptive analysis was performed. Patients had a mean age of 63.9 years, with 77.3% female. ALP lesions were most commonly vulval (72.2%) in females and penile (22.2%) in males. MU or cSCC precursor prevalence in ALP cohorts ranged from 0.9% to 4.2%. Human papillomavirus was rarely detected (8.4%), suggesting other mechanisms underlying MU development. The mean ALP duration prior to squamous dysplasia was 47.5 months. Metastases were present in 45.7% of cases that reported this outcome. MU treatment primarily involved surgical excision, with recurrence in 32.9% of cases and mortality in 21.1%. Poor disease control, erosive morphology, and long-standing lesions were associated with higher malignancy risk. Overall, this review highlights the malignant potential of ALP and underscores the importance of early detection and multidisciplinary care. Routine anogenital examinations, timely biopsies of suspicious lesions, and aggressive management of ALP may improve outcomes. Further research is needed to elucidate the mechanisms underlying MU development and optimize treatment strategies for this rare but morbid complication.
Related Concept Videos
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...


